Key result
Nitrendipine, 5-methylurapidil, and BMY 7378 blunted adrenergically induced renal vasoconstrictor responses by 25-35% (P<0.05) in both SHR and diabetic SHR.
Alpha(1A) and alpha(1D)-adrenoceptor subtypes contribute to mediating adrenergically induced constriction of the renal vasculature in both spontaneously hypertensive and diabetic hypertensive rats.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for alpha1A/D targeting in renal vasoconstriction; leaves open translation to human hypertension or diabetes.
Diabetes and hypertension are both associated with an increased risk of renal disease and are associated with neuropathies, which can cause defective autonomic control of major organs including the kidney. This study aimed to examine the alpha(1)-adrenoceptor subtype(s) involved in mediating adrenergically induced renal vasoconstriction in a rat model of diabetes and hypertension. 2. Male spontaneously hypertensive rats (SHR), 220-280 g, were anaesthetized with sodium pentobarbitone 7-day poststreptozotocin (55 mg x kg(-1) i.p.) treatment. The reductions in renal blood flow (RBF) induced by increasing frequencies of electrical renal nerve stimulation (RNS), close intrarenal bolus doses of noradrenaline (NA), phenylephrine (PE) or methoxamine were determined before and after administration of nitrendipine (Nit), 5-methylurapidil (5-MeU), chloroethylclonidine (CEC) and BMY 7378. 3. In the nondiabetic SHR group, mean arterial pressure (MAP) was 146+/-6 mmHg, RBF was 28.0+/-1.4 ml x min(-1) x kg(-1) and blood glucose was 112.3+/-4.7 mg x dl(-1), and in the diabetic SHR Group, MAP was 144+/-3 mmHg, RBF 26.9+/-1.3 ml(-1) min x kg(-1) and blood glucose 316.2+/-10.5 mg x dl(-1). Nit, 5-MeU and BMY 7378 blunted all the adrenergically induced renal vasoconstrictor responses in SHR and diabetic SHR by 25-35% (all P<0.05), but in diabetic rats the responses induced by RNS and NA treated with 5-MeU were not changed. By contrast, during the administration of CEC, vasoconstrictor responses to all agonists were enhanced by 20-25% (all P<0.05) in both the SHR and diabetic SHR. 4. These findings suggest that alpha(1A) and alpha(1D)-adrenoceptor subtypes contribute in mediating the adrenergically induced constriction of the renal vasculature in both the SHR and diabetic SHR. There was also an indication of a greater contribution of presynaptic adrenoceptors, that is, alpha(1B)-, and/or alpha(2)-subtypes.
No takes yet. Share an insight, caveat, or question.
Armenia et al. (2004) studied Diabetes and hypertension (animal model). Adrenoceptor antagonists (nitrendipine, 5-methylurapidil, chloroethylclonidine, BMY 7378) vs. Baseline / nondiabetic SHR was evaluated on Reductions in renal blood flow (RBF) induced by electrical renal nerve stimulation and adrenoceptor agonists (p=<0.05). Nitrendipine, 5-methylurapidil, and BMY 7378 blunted adrenergically induced renal vasoconstrictor responses by 25-35% (P<0.05) in both SHR and diabetic SHR.
Synapse has enriched 10 related papers. Consider them for comparative context: